Andere Sprachen Nxera Pharma Co., Ltd.

Aktien

A0B7EK

JP3431300007

4565

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 30.04.2024			% 5 Tage	% 1. Jan.
1’468 ^JPY	+0.69%		-0.81%	+3.31%

16.04.	Nxera Pharma stellt erfolgreiche Entwicklungsfortschritte des Schizophrenie-Kandidaten NBI-1117568 fest	CI
15.04.	Nxera Pharma kündigt exklusive Liefer- und Vertriebsvereinbarung mit Handok für Pivlaz in Südkorea an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	18.04.
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan	17.04.
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	17.04.
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16.04.
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16.04.
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	16.04.
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea	15.04.
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	15.04.
Nxera Pharma joins the World Orphan Drug Alliance	08.04.
Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC	03.04.
Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC	03.04.
Sosei Group Corporation will Change its Name to Nxera Pharma Co., Ltd	01.04.
Nxera Pharma is the New Name for Sosei Group	01.04.
Sosei Shareholders Greenlight Name Change, Top Management Appointments	28.03.
Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma	27.03.
Sosei Heptares Begins Phase 1 Trial for Novel Inflammatory Bowel Disease Treatment	22.03.
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease	21.03.
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	21.03.
Sosei Group Corporation Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	21.03.
Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease	21.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nxera Pharma Co., Ltd.

Aktien

A0B7EK

JP3431300007

4565

Andere Sprachen

Filter